Patents by Inventor Jonathan Alexander Terrett

Jonathan Alexander Terrett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12146157
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7+ malignancies.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: November 19, 2024
    Inventors: Jonathan Alexander Terrett, Jason Sagert
  • Publication number: 20240352151
    Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.
    Type: Application
    Filed: March 4, 2024
    Publication date: October 24, 2024
    Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
  • Publication number: 20240115724
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 19, 2023
    Publication date: April 11, 2024
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI
  • Patent number: 11926676
    Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: March 12, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
  • Publication number: 20240076374
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 7, 2024
    Inventors: James William WEST, Jason Gary SAGERT, Jonathan Alexander TERRETT, Annie Yang WEAVER, Luc Roland DESNOYERS, Shweta SINGH
  • Publication number: 20230355761
    Abstract: Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of CD70+ solid tumors.
    Type: Application
    Filed: November 13, 2020
    Publication date: November 9, 2023
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • Publication number: 20230346836
    Abstract: A population of genetically engineered T cells, comprising a disrupted cbl-b gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; (c) reduced T cell exhaustion, and (d) enhanced cytotoxicity activity, as compared to non-engineered T cell counterparts.
    Type: Application
    Filed: December 21, 2022
    Publication date: November 2, 2023
    Inventors: Changan GUO, Hanspeter WALDNER, Jonathan Alexander TERRETT
  • Publication number: 20230303713
    Abstract: Genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting CD19 and having multiple genetic edits, including a disrupted TRAC gene, a disrupted ?2M gene, a disrupted Regnase 1 gene, and/or a disrupted TGFBRII gene. Also provided herein are methods of making such genetically engineered T cells and methods of using the genetically engineered T cells in cancer treatment.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 28, 2023
    Inventors: Mohammed Ghonime, Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee Dequeant
  • Publication number: 20230302053
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 28, 2023
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • Patent number: 11753466
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 12, 2023
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Publication number: 20230220059
    Abstract: Genetically engineered T cells expressing a chimeric antigen receptor (CAR) that binds B-cell maturation antigen (BCMA) and uses thereof for treating multiple myeloma, for example, refractory and/or relapsed multiple myeloma. The genetically engineered T cells may comprise a disrupted endogenous TRAC gene and/or a disrupted endogenous ?2M gene.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 13, 2023
    Inventors: Jonathan Alexander TERRETT, Ewelina MORAWA, Jason SAGERT, Annie Yang WEAVER
  • Publication number: 20230212283
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 7, 2022
    Publication date: July 6, 2023
    Applicant: Cytomx Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
  • Publication number: 20230181750
    Abstract: Mask peptides for use in producing masked antibodies specific to tyrosine-protein kinase-like 7 (PTK7). Also provided herein are masked anti-PTK7 antibodies comprising the mask peptide and therapeutic uses thereof.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 15, 2023
    Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
  • Patent number: 11649438
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
  • Patent number: 11622977
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 11, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20230044761
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: October 1, 2021
    Publication date: February 9, 2023
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20230021539
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: October 1, 2021
    Publication date: January 26, 2023
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20230021301
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 28, 2021
    Publication date: January 19, 2023
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA, Jason Gary SAGERT, Jonathan Alexander TERRETT, James William WEST
  • Patent number: 11548944
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 10, 2023
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Patent number: 11548943
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 10, 2023
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West